Q1 Earnings Forecast for BioLineRx Issued By HC Wainwright

BioLineRx Ltd. (NASDAQ:BLRX) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of BioLineRx in a research note issued on Monday, March 31st. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.84) per share for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($5.80) per share. HC Wainwright also issued estimates for BioLineRx’s Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.92) EPS and Q4 2025 earnings at ($0.99) EPS.

Several other brokerages have also recently commented on BLRX. StockNews.com cut shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th. Jones Trading reissued a “hold” rating on shares of BioLineRx in a research note on Wednesday.

BioLineRx Trading Down 5.2 %

BLRX opened at $2.94 on Wednesday. The firm has a 50 day simple moving average of $3.44 and a 200 day simple moving average of $10.51. BioLineRx has a fifty-two week low of $2.85 and a fifty-two week high of $35.60. The company has a market cap of $9.79 million, a price-to-earnings ratio of -0.33 and a beta of 1.39. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Institutional Investors Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC acquired a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx as of its most recent SEC filing. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.